It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.

Biointelect is a strategic planning and commercialisation firm for the biopharmaceutical and medical device sector including commercial, government and not-for-profit organisations.

Biointelect helps its clients develop and drive strategy, identify and evaluate new business opportunities and engage the right partners. The strategy consulting involves therapeutic development from start up through to post launch, with an Australian and a Global perspective.

Biointelect’s mission is to bring science to market.

Biocelect works with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market.

In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand.

Biocelect’s mission is to build pathways to patients.

In this Australian Health Journal interview, Jenny and Karl talk about  the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia.  The journey didn’t just include  talented and diverse skilled staff but also their children working in both organisations.